4
Changes in Ownership
CORCEPT THERAPEUTICS INC Filed Acc 0001193125-25-307282
Chief Development Officer sold 20,000 shares at an average $80.08 ($1,601,526)
- Chief Development Officer acquired 20,000 shares (option exercise)
- Chief Development Officer acquired 448 shares (grant or award)
- Chief Development Officer gave 787 shares (gift)
- Chief Development Officer acquired 787 shares (other)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Guyer William Chief Development Officer | 2025-12-01 | Grant or award 10b5-1 | +224 | $79.78 | $17,871 | 224 | D: show line 1 in the form |
| Guyer William Chief Development Officer | 2025-12-01 | Grant or award 10b5-1 | +224 | 448 | D: show line 2 in the form | ||
| Guyer William Chief Development Officer | 2025-12-02 | Gift 10b5-1 | −787 | 0 | I: show line 3 in the form | ||
| Guyer William Chief Development Officer | 2025-12-02 | Other acquisition 10b5-1 | +787 | 1,235 | D: show line 4 in the form | ||
| Guyer William Chief Development Officer | 2025-12-02 | Option exercise 10b5-1 | +20,000 | $21.65 | $433,000 | 21,235 | D: show line 5 in the form |
| Guyer William Chief Development Officer | 2025-12-02 | Sale 10b5-1 | −19,360 | $80.05 | $1,549,766 | 1,875 | D: show line 6 in the form |
| Guyer William Chief Development Officer | 2025-12-02 | Sale 10b5-1 | −640 | $80.88 | $51,760 | 1,235 | D: show line 7 in the form |
| Open-market sales · 20,000 sh · avg $80.08 · $1,601,526 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Guyer William Chief Development Officer | 2025-12-02 | Option exercise · Stock option (right to buy) 10b5-1 | −20,000 | 270,000 | D: show line 8 in the form |
Loading xslF345X05/ownership.xml…